%0 Journal Article
%T Mitigating temozolomide resistance in glioblastoma via DNA damage-repair inhibition
%A Harsh V. Jain
%A Inmaculada C. Sorribes
%A Samuel K. Handelman
%J -
%D 2020
%R 10.1098/rsif.2019.0722
%X Glioblastomas are among the most lethal cancers, with a 5 year survival rate below 25%. Temozolomide is typically used in glioblastoma treatment; however, the enzymes alkylpurine-DNA-N-glycosylase ..
%U https://royalsocietypublishing.org/doi/10.1098/rsif.2019.0722